TNFSF13B and lobular neoplasia: Rituximab (a biological DMARD that targets CD20 on B cells) can be combined with another DMARD for refractory LN, and the U.S. FDA recently approved belimumab (a biological DMARD that targets B-cell activating factor) for the treatment of cSLE in children who are more than 5-years-old (27).